Axcella Health Analyst Ratings
Axcella Health Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 12/15/2022 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 11/02/2022 | 1010.86% | Chardan Capital | $7 → $5 | Maintains | Buy |
| 10/03/2022 | 2121.73% | HC Wainwright & Co. | $8 → $10 | Maintains | Buy |
| 08/03/2022 | 1677.38% | HC Wainwright & Co. | $14 → $8 | Maintains | Buy |
| 08/03/2022 | 1233.04% | SVB Leerink | $9 → $6 | Maintains | Outperform |
| 05/09/2022 | 1455.21% | Chardan Capital | $12 → $7 | Maintains | Buy |
| 03/31/2022 | 1899.56% | SVB Leerink | $10 → $9 | Maintains | Outperform |
| 11/16/2021 | 2566.07% | Chardan Capital | $10 → $12 | Maintains | Buy |
| 10/12/2021 | 1233.04% | Noble Capital Markets | → $6 | Initiates Coverage On | → Outperform |
| 09/22/2021 | 1010.86% | Goldman Sachs | $9 → $5 | Downgrades | Buy → Neutral |
| 07/30/2021 | — | JP Morgan | Downgrades | Neutral → Underweight | |
| 07/06/2021 | 3010.42% | HC Wainwright & Co. | → $14 | Initiates Coverage On | → Buy |
| 06/03/2021 | 2121.73% | Chardan Capital | $16 → $10 | Maintains | Buy |
| 10/27/2020 | 3454.77% | Chardan Capital | → $16 | Initiates Coverage On | → Buy |
| 10/26/2020 | 2121.73% | SVB Leerink | → $10 | Assumes | → Outperform |
| 09/25/2020 | 3010.42% | B. Riley Securities | → $14 | Initiates Coverage On | → Buy |
| 08/06/2020 | 2121.73% | SVB Leerink | $20 → $10 | Maintains | Outperform |
| 07/31/2020 | 5454.32% | Piper Sandler | → $25 | Initiates Coverage On | → Overweight |
| 05/28/2020 | 6120.84% | Wedbush | → $28 | Initiates Coverage On | → Outperform |
| 05/18/2020 | 4343.46% | SVB Leerink | $21 → $20 | Maintains | Outperform |
| 05/01/2020 | 2121.73% | BTIG | → $10 | Initiates Coverage On | → Buy |
| 11/15/2019 | 2343.9% | JP Morgan | $20 → $11 | Maintains | Overweight |
| 06/03/2019 | 4343.46% | JP Morgan | → $20 | Initiates Coverage On | → Overweight |
| 06/03/2019 | 5454.32% | Goldman Sachs | → $25 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 12/15/2022 | — | HC Wainwright公司 | 評級下調 | 購買→中性 | |
| 11/02/2022 | 1010.86% | 查爾丹資本 | $7 → $5 | 維護 | 買 |
| 10/03/2022 | 2121.73% | HC Wainwright公司 | $8 → $10 | 維護 | 買 |
| 08/03/2022 | 1677.38% | HC Wainwright公司 | $14 → $8 | 維護 | 買 |
| 08/03/2022 | 1233.04% | SVB Leerink | $9 → $6 | 維護 | 跑贏大盤 |
| 05/09/2022 | 1455.21% | 查爾丹資本 | $12 → $7 | 維護 | 買 |
| 03/31/2022 | 1899.56% | SVB Leerink | $10 → $9 | 維護 | 跑贏大盤 |
| 11/16/2021 | 2566.07% | 查爾丹資本 | $10 → $12 | 維護 | 買 |
| 10/12/2021 | 1233.04% | 來寶資本市場 | → $6 | 開始承保 | →跑贏大盤 |
| 09/22/2021 | 1010.86% | 高盛 | $9 → $5 | 評級下調 | 購買→中性 |
| 07/30/2021 | — | 摩根大通 | 評級下調 | 中性→減持 | |
| 07/06/2021 | 3010.42% | HC Wainwright公司 | → $14 | 開始承保 | →購買 |
| 06/03/2021 | 2121.73% | 查爾丹資本 | $16 → $10 | 維護 | 買 |
| 10/27/2020 | 3454.77% | 查爾丹資本 | → $16 | 開始承保 | →購買 |
| 10/26/2020 | 2121.73% | SVB Leerink | → $10 | 假設 | →跑贏大盤 |
| 09/25/2020 | 3010.42% | B.萊利證券 | → $14 | 開始承保 | →購買 |
| 08/06/2020 | 2121.73% | SVB Leerink | $20 → $10 | 維護 | 跑贏大盤 |
| 07/31/2020 | 5454.32% | 派珀·桑德勒 | → $25 | 開始承保 | →超重 |
| 05/28/2020 | 6120.84% | 韋德布什 | → $28 | 開始承保 | →跑贏大盤 |
| 05/18/2020 | 4343.46% | SVB Leerink | $21 → $20 | 維護 | 跑贏大盤 |
| 05/01/2020 | 2121.73% | BTIG | → $10 | 開始承保 | →購買 |
| 11/15/2019 | 2343.9% | 摩根大通 | $20 → $11 | 維護 | 超重 |
| 06/03/2019 | 4343.46% | 摩根大通 | → $20 | 開始承保 | →超重 |
| 06/03/2019 | 5454.32% | 高盛 | → $25 | 開始承保 | →購買 |
What is the target price for Axcella Health (AXLA)?
Axella Health(Axla)的目標價是多少？
The latest price target for Axcella Health (NASDAQ: AXLA) was reported by Chardan Capital on November 2, 2022. The analyst firm set a price target for $5.00 expecting AXLA to rise to within 12 months (a possible 1010.86% upside). 6 analyst firms have reported ratings in the last year.
查爾丹資本於2022年11月2日報道了阿克塞拉健康公司(納斯達克：AXLA)的最新目標價。這家分析公司將目標價定為5美元，預計Axla將在12個月內上漲至(可能上漲1010.86%)。6家分析公司在過去一年公佈了評級。
What is the most recent analyst rating for Axcella Health (AXLA)?
分析師對Axella Health(Axla)的最新評級是多少？
The latest analyst rating for Axcella Health (NASDAQ: AXLA) was provided by Chardan Capital, and Axcella Health maintained their buy rating.
分析師對阿克塞拉健康公司(納斯達克：AXLA)的最新評級由查爾丹資本提供，阿克塞拉健康公司維持買入評級。
When is the next analyst rating going to be posted or updated for Axcella Health (AXLA)?
Axcell a Health(Axla)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Axcella Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Axcella Health was filed on November 2, 2022 so you should expect the next rating to be made available sometime around November 2, 2023.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閲公共財務報表，與Axcella Health的高管和客户交談，以及收聽收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Axcell a Health的上一次評級是在2022年11月2日提交的，因此您應該預計下一次評級將在2023年11月2日左右的某個時候提供。
Is the Analyst Rating Axcella Health (AXLA) correct?
分析師對Axella Health(Axla)的評級正確嗎？
While ratings are subjective and will change, the latest Axcella Health (AXLA) rating was a maintained with a price target of $7.00 to $5.00. The current price Axcella Health (AXLA) is trading at is $0.45, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Axcell Health(Axla)評級維持不變，目標價在7.00美元至5.00美元之間。Axella Health(Axla)目前的股價為0.45美元，超出了分析師的預測區間。
譯文內容由第三人軟體翻譯。